The combi-targeting concept: Dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 3, 2004, Pages 1163-1170

  Matheson, Stephanie L ^a   McNamee, James P ^a   Wang, Taiqui ^a   Alaoui Jamali, Moulay A ^a   Tari, Ana M ^a   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3 TOLYLAMINO) 6 QUINAZOLINYL] 3 METHYLTRIAZENE; 6 AMINO 4 (3 METHYLANILINO)QUINAZOLINE; 6 O METHYLGUANINE; 7 METHYLGUANINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SMA 41; SMA 52; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENE TARGETING; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MITOSIS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BODY WEIGHT; CELL CYCLE; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMET ASSAY; DNA DAMAGE; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; EPIDERMAL GROWTH FACTOR; FLOW CYTOMETRY; HUMANS; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM TRANSPLANTATION; NEOPLASMS; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 10044268467     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.071977     Document Type: Article

References (33)

1. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson RI, et al. (2001) Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor-α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61:6500-6510.
2. Allen LF, Lenehan PF, Eiseman IA, Elliott WL, and Fry DW (2002) Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 29:11-21.
3. Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, and Margison GP (1993) Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67:1299-1302.
4. Baselga J, Rischin D, Ranson M, Calvert AH, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, et al. (2002) Phase I safety, pharmacokinetic and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clinical Oncol 20:4292-4302.
5. 6-methylguanine and the cytotoxicity of methylating agents. Mutat Res 462:71-82.
6. Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, and Jean-Claude BJ (2002) Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-Triazene" BJ2000, a new probe for combi-targeting postulates. J Pharmacol Exp Ther 303:238-246.
7. Charkravarti A, Dicker A, and Mehta M (2004) The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Rad Oncol Biol Phys 58:927-931.
8. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, and Tortora G (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063.
9. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, et al. (1998) Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci 95:12022-12027.
10. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, and Ono M (2002) ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62:2554-2560.
11. Kaur H and Halliwell B (1996) Measurement of oxidized and methylated DNA bases by HPLC with electrochemical detection. Biochem J 318:21-23.
12. Kokkinakis DM, Ahmed MM, Delgado R, Fruitwala MM, Mohiuddin M, and Albores-Saavedra J (1997) Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents. Cancer Res 57:5360-5368.
13. 6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res 7:421-428.
14. 6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer 80:744-750.
15. Lammering G, Hewit TH, Valerie K, Contessa JN, Amorino GP, Dent P, and Schmidt-Ullrich RK (2003) EGFRvIII RK-mediated radioresistance through a strong cytoprotective response. Oncogene 22:5545-5553.
16. Magné N, Fischel JL, Dubreuil A, Formento P, Poupon M, Laurent-Puig P, and Milano G (2002) Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ('Iressa'). Br J Cancer 86:1518-1523.
17. Matheson SL, Brahimi F, and Jean-Claude BJ (2004) The combi-targeting concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41. Biochem Pharmacol 67:1131-1138.
18. Matheson SL, McNamee J, and Jean-Claude BJ (2001) Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumour targeting strategy. J Pharmacol Exp Ther 296:832-840.
19. Matheson SL, McNamee J, and Jean-Claude BJ (2003a) Differential responses of EGFR/AGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemother Pharmacol 51:11-20.
20. 14C]methyl triazene: a radiolabeled probe for the combi-targeting concept. J Label Compd Radiopharm 46:729-735.
21. McNamee JP, McLean JRN, Ferrarotto CL, and Bellier PV (2000) Comet assay: rapid processing of multiple samples. Mutat Res 466:63-69.
22. Mitsui H, Takuwa N, Maruyama T, Maekawa H, Hirayama M, Sawatari T, Hashimoto N, Takuwa Y, and Kimura S (2001) The MEK1-ERK MAP kinase pathway and the PI3 kinase-Akt pathway independently mediate anti-apoptotic signals in HEPG2 liver cancer cells. Int J Cancer 92:55-62.
23. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, and Wong AJ (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536-5539.
24. Nelson JM and Fry DW (2001) Akt, MAPK (Erk1/2) and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 276:14842-14847.
25. Qiu Q, Dudouit F, Matheson SL, Brahimi F, Banerjee R, McNamee JP, and Jean-Claude BJ (2003) The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties. Cancer Chemother Pharmacol 51:1-10.
26. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, and Lee C (1998) Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulatad growth of human prostatic carcinoma cells. Br J Cancer 77:855-861.
27. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, and Kris MG (2000) Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892.
28. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, and Nesland JM (2002) EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196:17-25.
29. Tentori L, Turriziani M, Franco D, Serafino A, Levati L, Roy R, Bonmassar E, and Graziani G (1999) Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia 13:901-909.
30. Vindelov LL (1977) Flow cytometric analysis of nuclear DNA in cells from solid tumor cell suspensions. A new method for rapid isolation and straining of nuclei. Virchows Arch B Cell Pathol 24:227-242.
31. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, and Gibson KH (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749-5754.
32. Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN, and Bates SE (1997) Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Nat Cancer Inst 89:1505-1515.
33. Yang Q, Hergenhahn M, Weninger A, and Bartsch H (1999) Cigarette smoke induces direct DNA damage in the human B-lympoid cell line Raji. Carcinogenesis 20:1769-1774.